At its Annual General Meeting, SoftOx AS is pleased to announce the election of
Dr. Tore Duvold as a new member of the Board of Directors.

Dr. Duvold brings over 25 years of experience in the life science sector,
including leadership roles in biotech, pharma, and public innovation funding. He
currently serves as CEO of the Swedish diagnostics company Spermosens AB and has
held senior positions at LEO Pharma, Aker Biopharma AS, Innovation Fund Denmark,
Edvince AB, and Coegin Pharma. In addition, he has served on the board of
Medicon Valley Alliance and been involved in several board roles.

"SoftOx's technology platform has strong potential to address major global
health challenges related to infection and antimicrobial resistance," said Dr.
Tore Duvold. "I look forward to contributing to the company's development and
value creation in the coming years."

Ulrik Spork, Chairman of the Board, welcomed the appointment:
"We are very pleased to have Tore join the board. His deep sector knowledge and
experience in driving innovation and partnerships will strengthen SoftOx as we
continue to advance our strategy and position the company for future growth."

For further information, please contact:
Ulrik Spork, COB Soft Solutions AS, +45 31 38 83 87
Ingrid Juven, CFO SoftOx Solutions AS, +47 918 76 165 
Mail: ir@soft-ox.com  
 
About SoftOx Solutions AS: 
SoftOx Solutions AS (ticker: SOFTX) is a clinical-stage pharmaceutical company
listed on Euronext Growth Oslo. The company is developing highly effective
pan-antimicrobial pharmaceuticals targeting bacteria, viruses, and fungi. The
technology is based on extensive research and development in partnership with
leading Nordic research institutes.